Related Experiment Videos
Lipoprotein(a) as a strong indicator for cerebrovascular disease
Insights
Lipoprotein(a) (Lp(a)) levels are significantly elevated in patients with cerebrovascular disease (CVD), indicating Lp(a) is a risk factor for both CVD and coronary artery disease (CAD).
Area of Science:
- Cardiovascular Research
- Neurology
- Lipidology
Background:
- Lipoprotein(a) (Lp(a)) is a lipoprotein particle implicated in cardiovascular disease.
- The role of Lp(a) in cerebrovascular disease (CVD) requires further elucidation.
- Understanding Lp(a) levels in CVD patients is crucial for risk stratification.
Purpose of the Study:
- To evaluate the role of Lp(a) in patients diagnosed with cerebrovascular disease (CVD).
- To compare Lp(a) serum levels in CVD patients with a healthy control group (CO) and a coronary artery disease (CAD) group.
- To investigate the correlation between Lp(a) levels and the severity of vascular lesions in the carotid system.
Main Methods:
- Cross-sectional study comparing three groups: healthy controls (n=37), CVD patients (n=46), and CAD patients (n=28).
- Measurement of serum Lp(a) levels and standard lipid parameters (TC, HDL-C, TG, LDL-C).
- Quantification of carotid artery stenosis using a Duplex Doppler scoring system.
Main Results:
- Median Lp(a) levels were significantly higher in the CVD group compared to the control group (p < 0.01).
- Lp(a) levels in the CVD group did not significantly differ from the CAD group.
- No significant differences in total cholesterol, HDL-C, TG, LDL-C, or LDL-C/HDL-C ratio were observed between control and CVD groups.
- A significant positive correlation was found between Lp(a) levels and the Duplex Doppler score in CVD patients aged 40-65 (r = 0.34, p < 0.01).
Conclusions:
- Elevated Lp(a) levels are associated with cerebrovascular disease.
- Lipoprotein(a) is identified as a significant risk factor for both coronary artery disease and cerebrovascular disease.
- Lp(a) may play a critical role in the pathogenesis of atherosclerosis in both arterial systems.
Abstract:
To evaluate the role of lipoprotein(a) (Lp(a] in patients with cerebrovascular disease (CVD), lipid parameters were compared with a control group (CO). Additionally, the Lp(a) serum levels were investigated in a coronary artery disease (CAD) group. The CO was made up of 37 healthy persons (age: 54.5 +/- 7.7, 26 males and 11 females), the CVD group included 46 patients with sustained transient ischemic attack (TIA) prolonged reversible ischemic neurologic deficits (PRIND) and cerebral infarction (CI) (age: 53.6 +/- 9.7, 32 males and 14 females), and the CAD group was made up of 28 survivors of myocardial infarctions (age: 52.5 +/- 8.1, 18 males and 10 females). The median values of Lp(a) in CVD were significantly higher than in the CO (p less than 0.01) and did not differ significantly from the CAD. Total TC, HDL-C, TG, LDL-C and the ratio of LDL-C/HDL-C did not show any significant difference between the control and cerebrovascular disease group. For quantification of the vascular lesions of the carotid system, a Duplex Doppler score system was used. The score correlated with Lp(a) in patients between 40 to 65 years of age (r = 0.34, p less than 0.01). Thus, we conclude that Lp(a) is not only a risk factor for CAD but also for CVD.